These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 8667603)

  • 1. A case of acute exacerbation of chronic hepatitis B accompanied by antibody to HBeAg with remission of liver damage after long-term treatment with interferon.
    Muraoka H; Sanefuji T; Keida R; Tsuji R; Abe H; Uchimura Y; Noguchi S; Suzuki H; Sata M; Tanikawa K
    Kurume Med J; 1995; 42(4):307-11. PubMed ID: 8667603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequent and rapid emergence of mutated pre-C sequences in HBV from e-antigen positive carriers who seroconvert to anti-HBe during interferon treatment.
    Günther S; Meisel H; Reip A; Miska S; Krüger DH; Will H
    Virology; 1992 Mar; 187(1):271-9. PubMed ID: 1736529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant interferon-alpha 2a hastens the rate of HBeAg clearance in children with chronic hepatitis B.
    Barbera C; Bortolotti F; Crivellaro C; Coscia A; Zancan L; Cadrobbi P; Nebbia G; Pillan MN; Lepore L; Parrella T
    Hepatology; 1994 Aug; 20(2):287-90. PubMed ID: 8045488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatitis B virus variants with core gene deletions in the evolution of chronic hepatitis B infection.
    Marinos G; Torre F; Günther S; Thomas MG; Will H; Williams R; Naoumov NV
    Gastroenterology; 1996 Jul; 111(1):183-92. PubMed ID: 8698197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prednisolone withdrawal therapy enhances the effect of human lymphoblastoid interferon in chronic hepatitis B. INTERPRED Trial Group.
    Krogsgaard K; Marcellin P; Trepo C; Berthelot P; Sanchez-Tapias JM; Bassendine M; Tran A; Ouzan D; Ring-Larsen H; Lindberg J; Enriquez J; Benhamou JP; Bindslev N
    J Hepatol; 1996 Dec; 25(6):803-13. PubMed ID: 9007706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mixed cryoglobulinemia type II in chronic hepatitis B associated with HBe-minus HBV mutant: cellular immune reactions and response to interferon treatment.
    Löhr H; Goergen B; Weber W; Gödderz W; Meyer zum Büschenfelde KH; Gerken G
    J Med Virol; 1994 Dec; 44(4):330-5. PubMed ID: 7897364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Core promoter mutations of hepatitis B virus for the response to interferon in e antigen-positive chronic hepatitis B.
    Kanai K; Kako M; Aikawa T; Hino K; Tsubouchi H; Takehira Y; Iwabuchi S; Kawasaki T; Tsuda F; Okamoto H; Miyakawa Y; Mayumi M
    Am J Gastroenterol; 1996 Oct; 91(10):2150-6. PubMed ID: 8855739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose recombinant interferon therapy in anti-HBe-positive chronic hepatitis B in Asian Indians.
    Guptan RC; Thakur V; Malhotra V; Sarin SK
    J Gastroenterol Hepatol; 1998 Jul; 13(7):675-9. PubMed ID: 9715416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term remission of chronic hepatitis B after alpha-interferon therapy.
    Korenman J; Baker B; Waggoner J; Everhart JE; Di Bisceglie AM; Hoofnagle JH
    Ann Intern Med; 1991 Apr; 114(8):629-34. PubMed ID: 2003708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defects in the precore region of the HBV genome in patients with chronic hepatitis B after sustained seroconversion from HBeAg to anti-HBe induced spontaneously or with interferon therapy.
    Takeda K; Akahane Y; Suzuki H; Okamoto H; Tsuda F; Miyakawa Y; Mayumi M
    Hepatology; 1990 Dec; 12(6):1284-9. PubMed ID: 2258145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation of nucleotide 1,762 in the core promoter region during hepatitis B e seroconversion and its relation to liver damage in hepatitis B e antigen carriers.
    Lindh M; Gustavson C; Mårdberg K; Norkrans G; Dhillon AP; Horal P
    J Med Virol; 1998 Jul; 55(3):185-90. PubMed ID: 9624604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic heterogeneity in the precore region of hepatitis B virus in hepatitis B e antigen-negative chronic hepatitis B patients: spontaneous seroconversion and interferon-induced seroconversion.
    Karasawa T; Aizawa Y; Zeniya M; Kuramoto A; Shirasawa T; Toda G
    J Med Virol; 1995 Apr; 45(4):373-80. PubMed ID: 7666040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative assessment of serum IgM anti-HBc in the natural course and during interferon treatment of chronic hepatitis B virus infection.
    Marinos G; Smith HM; Naoumov NV; Williams R
    Hepatology; 1994 Feb; 19(2):303-11. PubMed ID: 8294088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody--and hepatitis B virus DNA--positive chronic hepatitis B.
    Andreone P; Cursaro C; Gramenzi A; Zavagliz C; Rezakovic I; Altomare E; Severini R; Franzone JS; Albano O; Ideo G; Bernardi M; Gasbarrini G
    Hepatology; 1996 Oct; 24(4):774-7. PubMed ID: 8855175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of T-helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus.
    Marinos G; Torre F; Chokshi S; Hussain M; Clarke BE; Rowlands DJ; Eddleston AL; Naoumov NV; Williams R
    Hepatology; 1995 Oct; 22(4 Pt 1):1040-9. PubMed ID: 7557849
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative assessment of IgM antibodies towards an immunodominant B-cell epitope within the preS2 domain of HBV in the natural course and during combined prednisone/interferon alpha 2b treatment of chronic hepatitis B virus infection.
    Fei GZ; Sylvan SP; Hellström UB; Yao GB
    J Med Virol; 1995 Jun; 46(2):138-43. PubMed ID: 7636501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of decompensated viral hepatitis B-induced cirrhosis with low doses of interferon alpha.
    Nevens F; Goubau P; Van Eyken P; Desmyter J; Desmet V; Fevery J
    Liver; 1993 Feb; 13(1):15-9. PubMed ID: 8455421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphoblastoid interferon alfa with or without steroid pretreatment in children with chronic hepatitis B: a multicenter controlled trial.
    Gregorio GV; Jara P; Hierro L; Diaz C; de la Vega A; Vegnente A; Iorio R; Bortolotti F; Crivellaro C; Zancan L; Daniels H; Portmann B; Mieli-Vergani G
    Hepatology; 1996 Apr; 23(4):700-7. PubMed ID: 8666320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis B virus precore mutations and HBeAg negative reactivation of chronic hepatitis B after interferon therapy.
    Talbodec N; Loriot MA; Gigou M; Guigonis V; Boyer N; Bezeaud A; Erlinger S; Benhamou JP; Marcellin P
    Liver; 1995 Apr; 15(2):93-8. PubMed ID: 7540713
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon alfa-2b treatment of HBeAg negative/serum HBV DNA positive chronic active hepatitis type B.
    Hadziyannis S; Bramou T; Makris A; Moussoulis G; Zignego L; Papaioannou C
    J Hepatol; 1990; 11 Suppl 1():S133-6. PubMed ID: 2079571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.